BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results

BioMarin Pharmaceutical (NASDAQ:BMRN) posted its quarterly earnings data on Thursday. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25, FiscalAI reports. The business had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.The company’s revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.44 earnings per share. BioMarin Pharmaceutical updated its FY 2026 guidance to 4.900-5.100 EPS.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• Second-quarter revenue rose 20% year over year to nearly $1 billion, supported by broad-based demand and the Amicus contribution. BioMarin raised its full-year revenue, VOXZOGO revenue, and non-GAAP EPS guidance.
• The Amicus integration is progressing ahead of expectations, with projected peak revenue of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI/OPFOLDA, plus approximately $220 million in annual cost synergies by 2028. Management expects meaningful EPS accretion beginning in 2027 and deleveraging roughly one year earlier than previously anticipated.
• VOXZOGO revenue increased 14% year over year, while treated children grew more than 20% globally despite a new U.S. competitor. Approximately 90% of U.S. patients remained on therapy, and BioMarin submitted a supplemental application for hypochondroplasia approval, potentially supporting a 2027 launch.
• BioMarin added BMN 820, an oral CCR2 inhibitor in Phase III development for focal segmental glomerulosclerosis, to its late-stage pipeline. The company also expects to pursue additional clinical-stage business-development opportunities over the next 12 to 18 months.
• Acquisition financing is increasing annual interest expense by approximately $200 million, or $50 million per quarter, while reduced cash balances are lowering interest income. These factors, along with higher operating expenses, contributed to lower year-over-year non-GAAP diluted EPS in the quarter.

BioMarin Pharmaceutical Stock Up 2.6%

Shares of BioMarin Pharmaceutical stock traded up $1.55 during trading hours on Thursday, hitting $61.46. The company had a trading volume of 3,446,826 shares, compared to its average volume of 1,585,874. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The company’s 50-day moving average is $58.06 and its two-hundred day moving average is $57.01. The company has a market cap of $11.88 billion, a P/E ratio of 44.86, a price-to-earnings-growth ratio of 0.46 and a beta of 0.24. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $66.28.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Viking Global Investors LP increased its position in shares of BioMarin Pharmaceutical by 13.8% during the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC increased its position in BioMarin Pharmaceutical by 12.7% during the fourth quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock worth $395,197,000 after buying an additional 754,807 shares during the period. Dimensional Fund Advisors LP increased its position in BioMarin Pharmaceutical by 48.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock worth $197,405,000 after buying an additional 1,076,568 shares during the period. Vestal Point Capital LP increased its position in BioMarin Pharmaceutical by 261.4% during the fourth quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock worth $178,290,000 after buying an additional 2,170,000 shares during the period. Finally, Northern Trust Corp lifted its stake in BioMarin Pharmaceutical by 0.4% in the third quarter. Northern Trust Corp now owns 1,662,268 shares of the biotechnology company’s stock valued at $90,028,000 after buying an additional 7,157 shares during the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Quarterly earnings and revenue beat estimates. BioMarin reported quarterly EPS of $1.20, above consensus estimates ranging from $0.94 to $0.96. Revenue rose 20% year over year to approximately $990 million, exceeding analysts’ expectations of about $932 million. BioMarin Pharmaceutical Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year EPS guidance was raised above expectations. Management now expects fiscal 2026 EPS of $4.90-$5.10, compared with the consensus estimate of $4.80. The company also cited stronger growth expectations for revenue and VOXZOGO, supporting the improved outlook. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: New products could strengthen longer-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, together with expected cost synergies, should accelerate revenue growth, expand operating margins, increase cash flow and be accretive to non-GAAP EPS through the mid-2030s. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Revenue guidance was maintained broadly in line with consensus. Full-year revenue guidance of approximately $3.9 billion matched analysts’ expectations, so the principal upside came from the stronger-than-expected earnings outlook rather than a revenue forecast increase.
• Negative Sentiment: Reported EPS declined from the prior-year period. Quarterly EPS fell from $1.44 to $1.20, although the result still surpassed analyst estimates and revenue growth remained strong. BioMarin Q2 Earnings Snapshot

Analyst Ratings Changes

BMRN has been the subject of a number of recent research reports. UBS Group reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Royal Bank Of Canada decreased their price objective on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Sanford C. Bernstein lowered their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Weiss Ratings raised BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, June 26th. Finally, HC Wainwright restated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.09.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.